Back to list page

The MedTech Funding Mandate policy: supporting the uptake of innovations across the region - Heartflow

Posted: 10th November 2021

Heartflow is a non-invasive procedure that creates a personalised 3D model of the coronary arteries and analyses the impact that blockages have on blood flow.

It enables clinicians to identify significant coronary artery disease and determine the optimal treatment pathway thereby significantly cutting health care costs and leading to improved patient experiences and quality of life. Statistics show that more than half of patients who undergo invasive angiogram tests have no significant coronary blockage.

Heartflow is one of four innovations being supported by the MedTech Funding Mandate policy – a new national priority for NHS commissioners and seeks to spread innovations that have previously been supported by the Innovation Technology Tariff /Innovation Technology Payment ITP. Initially delayed by the pandemic, it launched on the 1st April 2021.The other products under the policy are:

  1. Placental growth factor-based testing – a blood test to rule out pre-eclampsia in pregnant women.
  2. SecurAcath – for securing percutaneous catheters.
  3. GammaCore – a handheld device which alleviates the symptoms of severe cluster headaches.

As an AHSN, part of our role is to help the adoption and spread of these innovations across our region.

Find out more in our video below.